Your session is about to expire
← Back to Search
Cetuximab After Immunotherapy for Head and Neck Cancer
Study Summary
This trial will study if Cetuximab is an effective treatment for those who have failed or cannot tolerate other immuno-oncology treatments or immuno-oncology treatments combined with chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 73 Patients • NCT01177956Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious wounds, ulcers, or bone fractures that are not healing.I haven't had serious heart issues or procedures in the last 6 months.I have previously been treated with drugs targeting the EGFR pathway.I have had lung conditions like pneumonitis or pulmonary fibrosis.I have not had a blood clot or pulmonary embolism in the last 6 months.My cancer is confirmed as squamous cell carcinoma in the head or neck.I have not had any major abdominal issues like fistula, perforation, or abscess in the last 28 days.I have been treated with immunotherapy targeting PD-1, alone or with chemotherapy.I have not had a stroke or mini-stroke in the last year.I am taking medication that could interact with Cetuximab.I am 18 years old or older.I am on stable corticosteroids for a rheumatologic condition but no other immunosuppressants.I can take care of myself and perform daily activities.
- Group 1: Cetuximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Cetuximab been given the green light from the Food and Drug Administration?
"Our safety score for cetuximab is a 2 due to its Phase 2 trial status, meaning that there have been studies conducted which back the compound's security but none proving its efficacy."
Has Cetuximab been previously explored in prior research?
"At present, there are 122 Cetuximab-related clinical trials in operation. Of those in progress, 30 have reached the Phase 3 stage. Dresden, Arizona is the primary hub for these studies; however, there exists a total of 5560 sites running tests with this medication worldwide."
To what extent is Cetuximab employed to treat medical conditions?
"Cetuximab is frequently prescribed for pharmacotherapy, and it has been known to effectively combat regionally advanced squamous cell carcinoma of the head and neck, metastatic squamous cell carcinoma of the head and neck (hnscc), as well as squamous cell carcinoma."
How many people have been recruited to participate in this experiment?
"Affirmative. The details found on clinicaltrials.gov show that this trial is currently seeking participants, having initially been posted on July 1st 2020 and last edited on August 5th 2022. Approximately 30 patients are being accepted by one medical facility."
Is there currently an opportunity to join this medical experiment?
"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially listed on July 1st 2020, is actively seeking patients. Approximately 30 individuals are needed to be recruited from one medical site."
Share this study with friends
Copy Link
Messenger